In last trading session, the stock price of Cannabis Science Inc (OTCMKTS:CBIS) declined more than 6% to close the day at $0.0152. Recently, the company released its growth projections based on its projects in-hand, cash-flow estimates, and current historic market developments. Key industry growth pointers indicate faster new drug launches, high-growth potential, and more advanced clinical trials through more than one lab compound.

The highlights

Cannabis Science commended legislators in seeking to advance access to cannabis for medicinal uses. It also appreciated the DEA for commencing an assessment on its scheduling of pot. Market could probably open up nearly 10 – 100 times to more than $300 Billion depending on streamlined FDA clinical studies access and improved pre-clinical trial acceptances.

The voting in California can result in increase of 100 – 1,000 times depending on easy laws to access medical pot based on age related regulations. This move could help the Cannabis industry surpass over $750 Billion.

Also, it sets the platform for a breakout year for Cannabis Science as the market grows. At a minimal 1% capture rate, the firm can record a combined inflow of revenues, with a complete turnaround in overall performance. They set this platform for high-growth in amidst DEA national industry changes for severe ailment treatments and historic California voting.

Cannabis Science has shifted its headquarters to Irvine, to be closer to distributers, suppliers, and strategic associates. It has commenced pre-clinical studies for five critical drugs for treatment of HIV/AIDS, cancer and other endemic neurological disorders. The company’s cannabinoid portfolio is broad and they are currently developing coherent drug development plans for active cannabinoid set.

In due course, the company applauded the success of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) in their Phase III study of a CBD-based product. It was developed to cure patients suffering from a rare type of epilepsy. The successful studies in Europe are helping firms in the relative industry to progress with their own trials in the U.S. and Europe.

Iddriven Inc (OTCMKTS:IDDR) In Need Of a New Catalyst

Iddriven Inc (OTCMKTS:IDDR) is in dire need of new PR, its sentiments having turned sour in the street. A series of pullbacks in the market comes even with the company announcing that it is building robust sales and marketing infrastructure in anticipation of robust growth for the year.

With the sentiments already priced in, investors would wish to know how it is doing on this front as competition in the sale of Identity and Access management solution continues to grow. Growth overseas has also emerged as a core objective for the enterprise company having signed a number of deals intended to expand wings abroad.

Deals with the likes of PATECCO are intended to expand Iddriven Inc (OTCMKTS:IDDR) footprint in Europe as it also relies on the likes of Zeva to grow some market share back at home.